Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Increase (Decrease) in Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

EDITAS MEDICINE, INC. Increase (Decrease) in Other Operating Liabilities

EDITAS MEDICINE, INC. (EDIT) reported Increase (Decrease) in Other Operating Liabilities of $1.27 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2025-03-05

  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for the quarter ending 2024-03-31 was $1.67M.
  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for the quarter ending 2023-03-31 was $0.00.
  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for the quarter ending 2020-12-31 was -$3.14M, a 379.00% decline year-over-year.
  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for the quarter ending 2020-09-30 was -$891.00K, a 269.71% decline year-over-year.
  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for fiscal 2024 was $1.27M, a 29.39% decline from fiscal 2023.
  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for fiscal 2023 was $1.80M.
  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for fiscal 2022 was $0.00.
  • EDITAS MEDICINE, INC. increase (decrease) in other operating liabilities for fiscal 2021 was $0.00.
Period endIncrease (Decrease) in Other Operating Liabilities 3 monthIncrease (Decrease) in Other Operating Liabilities 6 monthIncrease (Decrease) in Other Operating Liabilities 9 monthIncrease (Decrease) in Other Operating Liabilities 12 month
2024-12-31$1.27M
10-K · filed 2025-03-05
2024-03-31$1.67M
10-Q · filed 2024-05-08
2023-12-31$1.80M
10-K · filed 2025-03-05
2023-03-31$0.00
10-Q · filed 2024-05-08
2022-12-31$0.00
10-K · filed 2025-03-05
2021-12-31$0.00
10-K · filed 2024-02-28
2020-12-31-$3.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
-$4.03M
derived: sum of 2 quarters · filed 2023-02-22
-$3.52M
derived: sum of 3 quarters · filed 2023-02-22
-$2.68M
10-K · filed 2023-02-22
2020-09-30-$891.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$380.00K
derived: sum of 2 quarters · filed 2021-11-09
$453.00K
10-Q · filed 2021-11-09
$1.58M
derived: sum of 4 quarters · filed 2022-02-24
2020-06-30$511.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$1.34M
10-Q · filed 2021-08-05
$2.47M
derived: sum of 3 quarters · filed 2022-02-24
$2.99M
derived: sum of 4 quarters · filed 2022-02-24
2020-03-31$833.00K
10-Q · filed 2021-05-06
$1.96M
derived: sum of 2 quarters · filed 2022-02-24
$2.48M
derived: sum of 3 quarters · filed 2022-02-24
$1.60M
derived: sum of 4 quarters · filed 2022-02-24
2019-12-31$1.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$1.65M
derived: sum of 2 quarters · filed 2022-02-24
$771.00K
derived: sum of 3 quarters · filed 2022-02-24
$1.65M
10-K · filed 2022-02-24
2019-09-30$525.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
-$353.00K
derived: sum of 2 quarters · filed 2020-11-06
$528.00K
10-Q · filed 2020-11-06
2019-06-30-$878.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$3.00K
10-Q · filed 2020-08-07
2019-03-31$881.00K
10-Q · filed 2020-05-08
2018-12-31$1.03M
10-K · filed 2021-02-26
2017-12-31$8.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
-$13.00K
10-K · filed 2020-02-26
2017-09-30-$21.00K
10-Q · filed 2018-11-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30